Detalles de la búsqueda
1.
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 203(2): 351-363, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878152
2.
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Breast Cancer Res Treat
; 203(3): 497-509, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938495
3.
Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.
Oncologist
; 26(6): e996-e1008, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33325595
4.
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Eur J Clin Invest
; 51(7): e13535, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33662161
5.
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Br J Cancer
; 122(5): 603-612, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31839676
6.
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
Breast Cancer Res Treat
; 179(1): 161-171, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605311
7.
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.
Acta Oncol
; 59(12): 1438-1446, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32820683
8.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Lancet Oncol
; 20(3): 361-370, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30709633
9.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
10.
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat
; 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592543
11.
Mammaprint™: a comprehensive review.
Future Oncol
; 15(2): 207-224, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30156427
12.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet
; 389(10075): 1195-1205, 2017 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28215665
13.
Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.
Mod Pathol
; 30(9): 1204-1212, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28621322
14.
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 17(3): 357-366, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26822398
15.
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Breast Cancer Res Treat
; 155(3): 463-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26820652
16.
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Breast Cancer Res
; 17: 56, 2015 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25888246
17.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Lancet Oncol
; 15(10): 1137-46, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25130998
18.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet
; 382(9897): 1021-8, 2013 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23871490
19.
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Breast Cancer Res Treat
; 143(3): 485-92, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24395109
20.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Lancet Oncol
; 14(3): 244-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414588